M. Christiansen

发表

Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor

C. Sang, A. Vinik, J. Kessler, 2021, Clinical and translational science.

Performance of Omnipod Personalized Model Predictive Control Algorithm with Moderate Intensity Exercise in Adults with Type 1 Diabetes

Lauren M. Huyett, Joon Bok Lee, E. Dassau, 2019, Diabetes technology & therapeutics.

Performance of the Omnipod Personalized Model Predictive Control Algorithm with Meal Bolus Challenges in Adults with Type 1 Diabetes

Lauren M. Huyett, Joon Bok Lee, E. Dassau, 2018, Diabetes technology & therapeutics.

Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes

R. Vigersky, R. Slover, S. Garg, 2021, Diabetes technology & therapeutics.

The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System

T. Bailey, B. Bode, Mark P. Christiansen, 2015, Diabetes technology & therapeutics.

A New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device: Accuracy and User Performance Evaluation

Scott Pardo, Timothy S Bailey, Mark Christiansen, 2017, Journal of diabetes science and technology.

Clinical Accuracy of a Continuous Glucose Monitoring System With an Advanced Algorithm

T. Bailey, Mark P. Christiansen, Anna Chang, 2014, Journal of diabetes science and technology.

Accuracy of a Fourth-Generation Continuous Glucose Monitoring System in Children and Adolescents with Type 1 Diabetes.

R. Slover, L. Dimeglio, T. Bailey, 2018, Diabetes technology & therapeutics.

Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes

E. Budiman, T. Bailey, G. Forlenza, 2020, Journal of diabetes science and technology.

A new-generation continuous glucose monitoring system: improved accuracy and reliability compared with a previous-generation system.

Thomas Peyser, Mark Christiansen, T. Bailey, 2013, Diabetes technology & therapeutics.

Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects.

R. Das, T. Fu, R. Rupp, 2019, The Journal of infectious diseases.

Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study

A. Dehennis, S. Garg, T. Bailey, 2021, Diabetes technology & therapeutics.

Accuracy and User Performance Evaluation of a New, Wireless-enabled Blood Glucose Monitoring System That Links to a Smart Mobile Device

Scott Pardo, Timothy S Bailey, Mark Christiansen, 2017, Journal of diabetes science and technology.

Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.

Ronald Brazg, Timothy S Bailey, Mark Christiansen, 2014, Diabetes technology & therapeutics.

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

J. Rosenstock, S. Garg, T. Bailey, 2022, Nature Medicine.

Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm

Joon Bok Lee, E. Dassau, B. Buckingham, 2018, Diabetes technology & therapeutics.

Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.

S. Ajroud‐Driss, J. Kessler, Mark P. Christiansen, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.